- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01460589
Early Commencement of Adjuvant Chemotherapy for Colon Cancer (ECTX)
Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Trial
This study sets up the final study end point and three detailed goals as the following.
The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after surgery compared with conventional commencement after 2weeks for treatment of patients with colon cancer.
Detailed goal of study:
The primary endpoint: This study is designed to assess whether early commencement of adjuvant chemotherapy improves the 3-year disease-free survival, overall survival and recurrence rate.
The secondary endpoint: This study aims to compare short-term cumulative complications between early and conventional commencement of adjuvant chemotherapy after laparoscopic resection of colon cancer. This study will also assess the quality of life and side effects of chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment
- day1: Oxaliplatin 85mg/m2
- day1: Leucovorin 200mg/m2
day1: 5-FU 400mg/m2 IV bolus
- 2,400mg/m2 over 46 hours
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Daegu, Korea, Republic of, 700-721
- Kyungpook National University Hospital
-
Daegu, Korea, Republic of
- Gyu seog Choi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligibility rule of enrollment
- Rectal adenocarcinoma that were 15 cm or more from the anal verge
- pathologically diagnosed stage II or III disease
- patients who meet the discharge criteria within 10days after surgery
- Patients with adequate hepatic, renal, and bone marrow function, and a left ventricular ejection fraction of 55% or higher measured by echocardiography
Exclusion Criteria:
- An ineligibility to participate in the clinical study based on the judgment of investigators from a legal perspective
- A past history of chemotherapy
- tumor with obstruction or perforation
- tumor with distant metastases
- synchronous tumor
- relative or absolute contraindications of chemotherapy
- Recent MI, CVA, nitrate medication
- Severe cardiovascular disease, psychiatric disease
- Severe hepatic dysfunction (GOT, GPT ≥100IU/L)
- Renal dysfunction (Cr ≥2mg/dl)
- The concurrent presence of other severe medical diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: early commencement
Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
|
Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Other Names:
|
Active Comparator: conventional commencement
Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
|
Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year disease free survival rate
Time Frame: up to 3 years after operation
|
A survival analysis will be performed using the Kaplan-Meier method, for which a comparison of the survival curve will also made using a Log-rank test.
|
up to 3 years after operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
short-term cumulative surgery-related complications during chemotherapy
Time Frame: up to 26 weeks after operation
|
A comparison of the postoperative recovery variables, the postoperative complications and mortality
|
up to 26 weeks after operation
|
side effects of chemotherapy
Time Frame: during chemotherapy period
|
check Anemia, Leukopenia, Neutropenia, Thrombocytopenia, Edema, Fever, Insomnia, Asthenia, Anorexia, Nausea, Vomiting, Constipation, Diarrhea, Hand foot syndrome, Dyspepsia, Creatinine, AST, ALT, Bilirubin, abdominal pain, GI bleeding, diarrhea
|
during chemotherapy period
|
Collaborators and Investigators
Investigators
- Study Chair: Gyu seog Choi, M.D., Kyunpook National Univercity Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KNUHCRC004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on timing to initiate the adjuvant chemotherapy
-
Universidad Miguel Hernandez de ElcheMinisterio de Economía y Competitividad, SpainCompleted
-
King Abdullah International Medical Research CenterCompletedType1diabetes | Fasting HypoglycemiaSaudi Arabia
-
China Medical University HospitalActive, not recruitingThe Precision Personal Timeline in Definitive Surgery Associated With OutcomeTaiwan
-
Fudan UniversityNanfang Hospital of Southern Medical University; Ningbo Medical Center Lihuili... and other collaboratorsRecruitingNasopharyngeal CarcinomaChina
-
Karolinska InstitutetCompleted
-
ElmediXRecruitingAdvanced Cancer | Pancreatic Cancer MetastaticBelgium
-
Assiut UniversityNot yet recruiting
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.Active, not recruitingGlioblastoma Multiforme of BrainChina
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)CompletedOpioid-use DisorderUnited States
-
Instituto de Investigacion Sanitaria La FeKarolinska Institutet; Medical University of Vienna; Ain Shams University; Medical... and other collaboratorsRecruitingBreast CancerAustria, Sweden, Turkey, Argentina, Croatia, Egypt, Poland, Spain